Suppr超能文献

抗生素封管:庆大霉素与柠檬酸钠在37℃透析导管中的体外稳定性

Antibiotic lock: in vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37 degrees C.

作者信息

Battistella Marisa, Vercaigne Lavern M, Cote Dennis, Lok Charmaine E

机构信息

University Health Network-Toronto General Hospital, Toronto, Ontario, Canada.

出版信息

Hemodial Int. 2010 Jul;14(3):322-6. doi: 10.1111/j.1542-4758.2010.00440.x. Epub 2009 Mar 24.

Abstract

Catheter-related bacteremia (CRB) is a major cause of morbidity and mortality especially among patients receiving hemodialysis. Antibiotic lock therapy represents a promising technique in the treatment of CRB. Several studies have evaluated antibiotics in combination with heparin as an interdialytic locking solution for prophylaxis of CRB. The objective of this study was to evaluate the stability of gentamicin and sodium citrate in hemodialysis catheters as an interdialytic lock. Solutions containing gentamicin 2.5 mg/mL and sodium citrate 40 mg/mL (4%) were prepared individually and in combination. The solutions were instilled into dialysis catheters and stored at 37 degrees C for 96 h. Samples were withdrawn randomly from catheter lumens at 24-hour intervals for 4 days and stored at -20 degrees C until analysis. The samples were analyzed with validated, stability-indicating HPLC assays. The luminal concentration of gentamicin 2.5 mg/mL, sodium citrate 40 mg/mL (4%), and the combination was determined on study days 0, 1, 2, 3, and 4. When gentamicin was combined with sodium citrate and stored at 37 degrees C in dialysis catheters, the solution showed no decrease in either the gentamicin or the sodium citrate concentrations over the 96-hour study period. The percent of the original concentration at 96 h was 102.4+/-1.03 for gentamicin and 102.9+/-1.25 for citrate (P=0.5556). The combination of gentamicin 2.5 mg/mL and sodium citrate 40 mg/mL (4%) can be retained in hemodialysis catheters for at least 96 h at 37 degrees C with no evidence of degradation.

摘要

导管相关菌血症(CRB)是发病和死亡的主要原因,尤其是在接受血液透析的患者中。抗生素封管疗法是治疗CRB的一种有前景的技术。几项研究评估了抗生素与肝素联合作为透析间期封管溶液预防CRB的效果。本研究的目的是评估庆大霉素和柠檬酸钠在血液透析导管中作为透析间期封管液的稳定性。分别制备含2.5mg/mL庆大霉素和40mg/mL(4%)柠檬酸钠的溶液以及二者的混合溶液。将这些溶液注入透析导管并在37℃下储存96小时。在4天内每隔24小时从导管腔中随机抽取样本,并在-20℃下储存直至分析。使用经过验证的、能指示稳定性的高效液相色谱法分析样本。在研究的第0、1、2、3和4天测定2.5mg/mL庆大霉素、40mg/mL(4%)柠檬酸钠以及二者混合溶液的管腔浓度。当庆大霉素与柠檬酸钠混合并在37℃下储存在透析导管中时,在96小时的研究期间,溶液中庆大霉素和柠檬酸钠的浓度均未降低。庆大霉素在96小时时的原始浓度百分比为102.4±1.03,柠檬酸钠为102.9±1.25(P = 0.5556)。2.5mg/mL庆大霉素和40mg/mL(4%)柠檬酸钠的组合在37℃下可在血液透析导管中保留至少96小时,且无降解迹象。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验